EN DE
Watch Oncoinvent ASA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oncoinvent ASA (ONCIN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Oncoinvent ASA stock NOK 21.00, price NOK 62.60, that is 66.5% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · ISIN NO0013251173

OA Oncoinvent ASA logo Thin data Nov 9, 2026

Oncoinvent ASA

ONCIN · OL
Very expensive, weak quality

Our calculation puts a fair price 66% below what the stock costs today.

Low debt
Quality 46/100
Expensive Growth (revenue 3y +316.3 %/yr in NOK)
Revenue last quarter 31% below a year ago.
Fair value kr 21.00 · Strongly overvalued
Negative free cash flow
Trails peers (2/8)
Narrow moat 10/100 · thin data
Thin data
Watch Oncoinvent ASA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 134,668 kr 40.70 Fair Value kr 21.00 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range kr 40.70 – kr 134,668 · fair‑value band kr 13.86 – kr 26.25 · the kr 62.60 price screens above the kr 21.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Oncoinvent in your weekly email

Every Wednesday you see whether Oncoinvent is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer.

Show moreShow less

Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Stock analysis

Oncoinvent ASA (ONCIN) currently trades at kr 62.60, while our model-based Fair Value estimate is kr 21.00, 66% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: kr 13.86 (bear) to kr 26.25 (bull), the price of kr 62.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Oncoinvent ASA reported revenue of 28.1M NOK in FY2025 versus 774K NOK in FY2021, a compound +145.4%/yr. Reported net income was −155M NOK in FY2025.

Key figures

Market cap 375M NOK (≈ $39.7M) Micro · P/S ratio 17.2 · EPS (TTM) kr −83.20 · Return on equity −228% · Return on assets (EBIT) −106% (5-year average) · Operating margin −841% · Revenue (TTM) 24.3M NOK · Revenue growth (YoY) −31.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 54% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −66%, ONCIN screens richer than that median.

Fair Value models

Bear kr 13.86 Fair Value kr 21.00 Bull kr 26.25
Price kr 62.60 · Downside -66.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 13.86 kr 21.00 kr 26.25 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 13.86 kr 21.00 kr 26.25 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 58
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3,210.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+316.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40,628.2% (2021) → −564.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ONCIN screens overvalued: fair value 66% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oncoinvent ASA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −66.5% · Below median
Profitability
Return on assets −75.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −31.4% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.56× · Pricier than median
P/S (12 months) 15.42× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ONCIN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ONCIN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs ONCIN
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ONCIN
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs ONCIN
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ONCIN
argenx SE ARGX $927.21 $908.40 −2% vs ONCIN
CSL Limited CSL A$200.77 A$183.04 −9% vs ONCIN
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ONCIN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ONCIN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oncoinvent ASA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oncoinvent ASA Fair Value". https://www.fairvalue-calculator.com/stock/ONCIN

Frequently asked questions

Is Oncoinvent ASA (ONCIN) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of kr 21.00 versus a price of kr 62.60, about 66% lower (overvalued).
What is the fair value of ONCIN?
Our model-based fair value for Oncoinvent ASA is kr 21.00 (as of Nov 9, 2026), built from audited fundamentals. The current price: kr 62.60.
What is the quality score of ONCIN?
Oncoinvent ASA has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncoinvent ASA (ONCIN)?
Our model-based price target is the fair value of kr 21.00 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario kr 13.86, optimistic scenario kr 26.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncoinvent ASA stock forecast for 2026?
Our models put fair value at kr 21.00, about 66% lower versus a price of kr 62.60 (overvalued). Cautious scenario kr 13.86, optimistic scenario kr 26.25. The calculation is refreshed regularly with new filings.
What is the revenue of Oncoinvent ASA (ONCIN)?
Oncoinvent ASA reported trailing-twelve-month revenue of about 24.3M NOK (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Oncoinvent ASA (ONCIN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncoinvent ASA it is kr 21.00 per share (as of Nov 9, 2026), against a price of kr 62.60. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Oncoinvent ASA stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ONCIN trades above its calculated fair value: price kr 62.60, fair value kr 21.00, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCIN?
No. The price is what the market pays today (kr 62.60); the fair value is what the company's own numbers justify (kr 21.00). For Oncoinvent ASA the two are kr 41.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncoinvent ASA worth?
The market values Oncoinvent ASA at about 375M NOK (market capitalisation, as of Nov 9, 2026). Per share that is kr 62.60; our models calculate a fair value of kr 21.00 per share.
What do the bullish and bearish scenarios say about ONCIN?
Our models span a range for Oncoinvent ASA: cautious scenario kr 13.86, base kr 21.00, optimistic kr 26.25 per share (as of Nov 9, 2026, price kr 62.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oncoinvent ASA (ONCIN)?
Balance-sheet figures for Oncoinvent ASA (as of Nov 9, 2026): return on equity −228.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is ONCIN from its 52-week high?
Oncoinvent ASA trades at kr 62.60, about 56% below its 52-week high of kr 141.50 and 54% above the low of kr 40.70 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 21.00 is for.
Which stocks are comparable to Oncoinvent ASA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncoinvent ASA stock attractive at the current price?
The data as of Nov 9, 2026: price kr 62.60, calculated fair value kr 21.00 (−66%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCIN calculated?
We run Oncoinvent ASA through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 21.00 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Oncoinvent ASA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncoinvent ASA (ONCIN)?
The closing price on Nov 6, 2026 was kr 62.60. Our model-based fair value is kr 21.00, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncoinvent ASA right now?
The price sits above even our optimistic bull case (kr 26.25). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 13.86 to kr 26.25) leaves room in how you read the outcome.

Key figures of Oncoinvent ASA

How large is the market capitalisation of Oncoinvent ASA (ONCIN)?
The market capitalisation of Oncoinvent ASA is 375M NOK (≈ $39.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncoinvent ASA (ONCIN)?
The price-to-sales ratio of Oncoinvent ASA is 17.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncoinvent ASA (ONCIN)?
Earnings per share at Oncoinvent ASA are kr −83.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Oncoinvent ASA (ONCIN)?
The return on equity (ROE) of Oncoinvent ASA is −228% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncoinvent ASA (ONCIN)?
On an EBIT basis the return on assets of Oncoinvent ASA is −106% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncoinvent ASA (ONCIN)?
The operating margin of Oncoinvent ASA is −841% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncoinvent ASA (ONCIN)?
Revenue at Oncoinvent ASA is growing −31.4% versus a year earlier (3y avg +316%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Oncoinvent ASA (ONCIN) generate?
The free cash flow of Oncoinvent ASA is −131M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Oncoinvent ASA in the live analysis

One click puts Oncoinvent ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.